These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2006-002744-28||Effektivitätsoptimierte und toxizitätsreduzierte Therapie des metastasierten Kolorektalkarzinoms in der First-line Therapie||2014-04-16||due-trials|
|Completed, but no date||2008-003779-37||Capecitabine and bevacizumab ± vinorelbine as 1st line treatment in HER2/neu-negative metastatic or locally advanced inoperable breast cancer patients||bad-data|
|Completed, but no date, and reported results||2010-021370-11||An open label, single arm trial to characterize patients with metastatic renal cell carcinoma treated with everolimus after failure of the first VEGF-targeted therapy.||bad-data|
|Completed, but no date, and reported results||2011-001138-40||First Line Pazopanib in Poor Risk Patients with Metastatic Renal Cell Carcinoma||bad-data|
|Reported results||2013-005329-22||An open label, randomized controlled prospective multicenter two arm phase IV trial to determine Patient preference for everolimus in combination with exemestane or capecitabine in combination with b...||2017-09-30||due-trials|
|Ongoing||2017-002930-22||A randomized, open-label, multicenter, two-arm, phase III study to evaluate efficacy and quality of life in postmenopausal patients with metastatic hormone receptor-positive HER2-negative breast cance...||not-yet-due|